An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 20 Sep 2023 Status changed from recruiting to completed.
- 19 Dec 2022 Planned End Date changed from 20 Dec 2022 to 31 Mar 2023.
- 19 Dec 2022 Planned primary completion date changed from 20 Dec 2022 to 31 Mar 2023.